PART I References to Roivant, the Company, we, us or our in the following section refer to Roivant Sciences Ltd. and its consolidated subsidiaries, unless the context otherwise requires. Overview Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivants pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositi...
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-05-29 | 2025-03-31 | 0001140361-25-020715 | EDGAR | 145K words |
| 2024-05-30 | 2024-03-31 | 0001140361-24-028145 | EDGAR | — |
| 2023-06-28 | 2023-03-31 | 0001140361-23-031798 | EDGAR | — |
| 2022-06-28 | 2022-03-31 | 0001193125-22-183362 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-06 | 2025-12-31 | 0001635088-26-000011 | EDGAR | 86K words |
| 2025-11-10 | 2025-09-30 | 0001635088-25-000016 | EDGAR | — |
| 2025-08-11 | 2025-06-30 | 0001140361-25-030001 | EDGAR | — |
| 2025-02-10 | 2024-12-31 | 0001140361-25-003661 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001140361-24-046019 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001140361-24-036642 | EDGAR | — |
| 2024-02-13 | 2023-12-31 | 0001140361-24-007260 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001140361-23-052721 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001140361-23-039406 | EDGAR | — |
| 2023-02-13 | 2022-12-31 | 0001140361-23-006180 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001140361-22-041175 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001193125-22-220561 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001140361-26-012885 | EDGAR | 1K words |
| 2026-03-03 | 0001140361-26-007548 | EDGAR | — |
| 2026-03-03 | 0001140361-26-007447 | EDGAR | — |
| 2026-02-06 | 0001635088-26-000009 | EDGAR | — |
| 2025-12-11 | 0001140361-25-045204 | EDGAR | — |
| 2025-11-10 | 0001140361-25-041269 | EDGAR | — |
| 2025-09-17 | 0001140361-25-035190 | EDGAR | — |
| 2025-09-11 | 0001140361-25-034711 | EDGAR | — |
| 2025-09-03 | 0001140361-25-033767 | EDGAR | — |
| 2025-08-11 | 0001140361-25-029998 | EDGAR | — |
112 total filings indexed. 86 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001635088 |
| Ticker | ROIV |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | D0 |
| Website | https://www.roivant.com |
| Listed | 2021-10-01 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report